Current scientific questions influencing patient management in advanced prostate cancer

Learning objective:         

After joining this meeting, participants should be able to:

• Describe the clinical benefits of earlier treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) and the consequences of disease progression
• Discuss the impact of new data on treatment and management decisions for individual patients with mHSPC and nmCRPC

Scientific Committee:

• Laura-Maria Krabbe (Germany)
• Bertrand Tombal (Belgium)

Faculty:

• Boris Hadaschik (Germany)
• Alexandre de la Taille (France)
• Jochen Walz (France)